ESG

Barrick Mining (NYSE:B) released its Summary Sustainability Report, highlighting six years of ESG progress since its merger. The company has distributed over $70 billion to stakeholders and focuses on UN Sustainable Development Goals, workplace safety, and greenhouse gas emission management. Barrick is transitioning to renewable energy and investing in community infrastructure like schools, clinics, and water projects. The Summary Report offers a simplified overview of Barrick’s global environmental and social impact alongside the comprehensive 2024 Sustainability Report.

Diginex (DGNX), a sustainability RegTech firm, grew revenue 57% to $2.0M but widened its net loss to $5.2M in FY2025. Critically, its balance sheet shifted from $23.0M net liabilities to $4.6M net assets after its January 2025 IPO. Post-filing, the company announced ambitious plans: a $2B all-stock acquisition of Resulticks Group, purchasing Matter DK ApS for $13M, pursuing a dual listing on Abu Dhabi Securities Exchange, and raising $250M targeting GCC investors. Strategic shifts included moving away from customization toward SaaS solutions despite core subscription growth challenges.

PT Bank Rakyat Indonesia (BRI) launched its inaugural IDR 5 trillion Sustainable Social Bond, attracting IDR 6.57 trillion in subscriptions, and becoming the first Indonesian bank to issue such a bond. The offering, part of a larger IDR 20 trillion program, aims to support inclusive and sustainable financing. The bond received a Triple A rating and features varied tenors and interest rates. This move reinforces BRI’s commitment to ESG and sustainable financial practices.

Prime Mining Corp. announced a successful shareholder meeting with all proposals approved and directors elected. The company, focused on its Los Reyes gold-silver project in Mexico, has a strong cash balance and is on track to deliver a Preliminary Economic Assessment in Q3 2025. Shareholder engagement was high, demonstrating confidence in Prime’s future.

Innovent Biologics released its 2024 ESG Report outlining a five-pillar strategy—Excellent Governance, Advancing Public Health, Uncompromising Quality, Empowering Talent, and Sustainable Ecology. Achieving an MSCI AAA ESG rating (the only Chinese biotech recipient), it aligned with UN SDGs, expanded board diversity, and distributed RMB 3.6 billion in medicines to 200,000+ patients. The company maintained 100% GMP compliance, reduced energy use by 29%, saved 51,100 tons of water annually, and achieved 96.8% employee retention with 44.2% women in management roles. Its pipeline includes 13 orphan drugs and three New Drug Applications under review, underscoring its dual focus on innovation and sustainability.